ACE-gen polymorphism and cardiovascular diseases

Klinik und Poliklinik für Innere Medizin II, Universität Regensburg.
Herz (Impact Factor: 0.91). 03/2000; 25(1):1-6. DOI: 10.1007/BF03044118
Source: PubMed

ABSTRACT The angiotensin converting enzyme (ACE) is an integral part of enzymatic cascades leading to generation of angiotensin II as well as degradation of bradykinin. For this reason, it represents an important part for the metabolism of 2 vasoactive peptides. Early in this decade, convincing experimental evidence demonstrated the induction of this enzyme in several pathophysiological conditions including myocardial infarction and left ventricular hypertrophy. In parallel, a deletion/insertion (D/I) polymorphism of the human ACE gene was discovered that was related to 14 to 50% of the interindividual variance of serum ACE activity. More recently, this polymorphism was implicated in the pathogenesis of a variety of cardiovascular disorders including myocardial infarction, left ventricular hypertrophy, hypertension as well as nephropathy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiotensin-converting enzyme (ACE) is primarily localized (>90%) in various tissues and organs, most notably on the endothelium but also within parenchyma and inflammatory cells. Tissue ACE is now recognized as a key factor in cardiovascular and renal diseases. Endothelial dysfunction, in response to a number of risk factors or injury such as hypertension, diabetes mellitus, hypercholesteremia, and cigarette smoking, disrupts the balance of vasodilation and vasoconstriction, vascular smooth muscle cell growth, the inflammatory and oxidative state of the vessel wall, and is associated with activation of tissue ACE. Pathologic activation of local ACE can have deleterious effects on the heart, vasculature, and the kidneys. The imbalance resulting from increased local formation of angiotensin II and increased bradykinin degradation favors cardiovascular disease. Indeed, ACE inhibitors effectively reduce high blood pressure and exert cardio- and renoprotective actions. Recent evidence suggests that a principal target of ACE inhibitor action is at the tissue sites. Pharmacokinetic properties of various ACE inhibitors indicate that there are differences in their binding characteristics for tissue ACE. Clinical studies comparing the effects of antihypertensives (especially ACE inhibitors) on endothelial function suggest differences. More comparative experimental and clinical studies should address the significance of these drug differences and their impact on clinical events.
    The American Journal of Cardiology 11/2001; 88(9A):1L-20L. DOI:10.1016/S0002-9149(01)01878-1 · 3.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gegenwärtige Fortschritte in den pharmakologischen Wissenschaften erlauben einen ersten Ausblick auf eine individuelle, genotyp-basierende Arzneimitteltherapie, durch die sich die Effektivität der Medikamentenbenutzung weiter verbessern ließe. Die genotypische Erfassung von genetischen Polymorphismen, die bei Medikamentenreaktionen beteiligt sind, verspricht die Arzneimitteltherapie grundlegend zu optimieren, wenn damit Patienten identifiziert werden, für die ein Medikament entweder nutzbringend und sicher angewandt oder aber aufgrund zu erwartender Nebenwirkungen nicht eingesetzt werden sollte. Die neuen pharmakogenomischen Behandlungsstrategien werfen komplexe ethische Fragestellungen auf, da durch ein genetisches Screening für Arzneimittelzwecke asymptomatische Patienten mit erhöhtem Risiko für eine insgesamt schlechtere Prognose identifiziert werden könnten. Die Pharmakogenomik beeinflusst damit das Beziehungsverhältnis zwischen behandelnden Arzt und Patienten, das traditionell auf Diskretion, Vertraulichkeit und dem unbedingten Vorsatz, heilen und keinesfalls schaden zu wollen, beruht. Der vorliegende Aufsatz diskutiert einige ethische Aspekte im Bedeutungswandel der Arzt-Patienten-Beziehung, der durch diesen neuartigen pharmakogenomischen Behandlungsansatz ausgelöst wird. Definition of the problem: Recent progress in the pharmacological sciences provides a first glimpse of the development of an individual, genotype-based drug therapy in order to improve the efficiency of drug utilization. Genotyping of genetic polymorphisms in genes involved in drug response promises to optimize drug therapy fundamentally by identifying patients for whom a pharmaceutical agent may be effective and safe or contraindicated because of expected adverse drug reactions. Arguments: The new pharmacogenomic treatment strategies raise complex bioethical issues, because genetic screening for drug therapy may identify asymptomatic patients who are at risk for a particular adverse outcome. Thus, pharmacogenomics will affect the relationship between the treating physician and the patient which is traditionally based on privacy, confidentiality, beneficience and non-maleficience. Conclusion: In the article presented some ethical aspects of these new pharmacogenomic approaches concerning the physician-patient relationship are discussed.
    Ethik in der Medizin 02/2002; 14(1):3-10. DOI:10.1007/s00481-002-0157-6 · 0.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genetic bases for novel prothrombotic, inflammatory risk factors may play a role in the early onset of coronary artery disease. Twenty-one patients below 35 years of age who underwent coronary bypass grafting between 2002 and 2004 constituted the study group and were compared with 50 healthy, age and sex-matched controls. Gene analysis for genetic polymorphisms of angiotensin-converting enzyme, prothrombin G20210A, tumour necrosis factor-alpha G308A, factor V Leiden and interleukin-6 genes was carried out. The control group was 98% homozygous for the factor V Leiden GG allele and 2% heterozygous for the GA allele. On the other hand, the study group was 76.2% homozygous for the GG allele, and 23.8% heterozygous for the GA allele (P<0.05). Homozygosity for factor V Leiden mutation (AA) was not encountered in either group. With regard to interleukin-6, 70.0% of the control group demonstrated homozygosity for the GG allele and 30.0% showed heterozygosity (GC). The study group was 52.4% homozygous for the GG allele and heterogenicity was similar in this group (28.6% GC). On the other hand, 19.0% of this group demonstrated CC homogenicity (P<0.05). No difference was observed with regard to gene polymorphisms. Gene polymorphisms with regard to prothrombotic factor V Leiden mutation and inflammatory marker interleukin-6 may play a role in the pathogenesis of early-onset coronary artery stenosis in patients below 35 years of age.
    Coronary Artery Disease 03/2006; 17(1):35-9. DOI:10.1097/00019501-200602000-00006 · 1.30 Impact Factor
Show more